Anika Therapeutics, Inc. 8-K

What Happened
Anika Therapeutics, Inc. announced board-approved amendments to its equity compensation plans and confirmed that stockholders approved the changes at its 2026 Annual Meeting. The Board adopted the amendments on April 26, 2026 (with a revised adoption on June 8, 2026), and the amended plans were effective June 18, 2026 as filed in the 8‑K.

Key Details

• The 2017 Omnibus Incentive Plan reserve was increased by 350,000 shares, from 5,760,000 to 6,110,000 shares.
• All 6,110,000 shares under the amended 2017 Plan may be granted as incentive stock options under Section 422 of the Internal Revenue Code.
• The 2021 Employee Stock Purchase Plan (ESPP) reserve was increased by 200,000 shares, from 200,000 to 400,000 shares.
• The full text of the amended plans was filed as exhibits to the Form 8‑K (Exhibits 10.1 and 10.2).

Why It Matters
These changes increase the pool of shares available for employee and director awards, which enables the company to grant additional stock-based compensation (including tax-favored incentive stock options). For investors, that means potential dilution when new awards are granted and exercised—something to monitor in future equity grant disclosures and dilution metrics. The filings provide the exact amended plan terms for anyone tracking executive compensation or shareholder dilution.